Home Phototherapy Improves Access to Dermatologic Care: A Novel Stakeholder Alliance to Facilitate Its Implementation by Bawany F, Ryan Wolff J, Ritchlin CT, Tausk F

Get full text

GRAPPA 2018 project report by Goel, N, Fitzgerald, O, Gladman, DD, Helliwell, PS, Kavanaugh, A, Maksymowych, WP, Mease, PJ, Ritchlin, CT, Coates, LC

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-bl... by Ritchlin, CT, Coates, LC, Mease, PJ, van der Heijde, D, Song, J, Jiang, Y, Shawi, M, Kollmeier, AP, Rahman, P

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite mea... by Mease, PJ, Gladman, DD, Collier, D, Ritchlin, CT, Helliwell, P, Coates, LC, Strand, V, Liu, L, Kricorian, G, Chung, J

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from t... by Orbai, AM, Coates, LC, Deodhar, A, Helliwell, P, Ritchlin, CT, Kollmeier, A, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis by Pournara, E, Kormaksson, M, Nash, P, Ritchlin, CT, Kirkham, BW, Ligozio, G, Pricop, L, Ogdie, A, Coates, LC, Schett, G, McInnes, IB

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy by Krueger, JG, Eyerich, K, Kuchroo, VK, Ritchlin, CT, Abreu, MT, Elloso, MM, Fourie, A, Fakharzadeh, S, Sherlock, JP, Yang, Y, Cua, DJ, McInnes, IB

Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phas... by Orbai, A-M, Coates, LC, Deodhar, A, Helliwell, PS, Ritchlin, CT, Leibowitz, E, Kollmeier, AP, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis by Coates, L, Ritchlin, CT, Gossec, L, Helliwell, PS, Rahman, P, Kollmeier, AP, Xu, XL, Shawi, M, Karyekar, CS, Contré, C, Noël, W, Sheng, S, Wang, Y, Xu, S, Mease, PJ

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free by Coates, LC, Ritchlin, CT, Gossec, L, Helliwell, P, Rahman, P, Hsia, EC, Kollmeier, A, Xu, XL, Karyekar, C, Shawi, M, Noel, W, Jiang, Y, Sheng, S, Wang, Y, Mease, PJ

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Mease, PJ, Merola, JF, Tanaka, Y, Gossec, L, McInnes, IB, Ritchlin, CT, Landewé, RBM, Asahina, A, Ink, B, Heinrichs, A, Bajracharya, R, Shende, V, Coarse, J, Coates, LC

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active... by Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R

GRAPPA 2019 project report by Goel, N, Coates, LC, De Marco, G, Eder, L, FitzGerald, O, Helliwell, PS, Leung, YY, Maksymowych, WP, Mease, PJ, Østergaard, M, O’Sullivan, D, Poddubnyy, D, Ritchlin, CT, Gladman, DD

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) by McInnes, IB, Asahina, A, Coates, LC, Landewé, R, Merola, JF, Ritchlin, CT, Tanaka, Y, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Mease, PJ

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Coates, LC, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gosse, L, Orbai, A-M, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Merola, JF

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-contr... by Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis by Singh, JA, Guyatt, G, Ogdie, A, Gladman, DD, Deal, C, Deodhar, A, Dubreuil, M, Dunham, J, Husni, ME, Kenny, S, Kwan-Morley, J, Lin, J, Marchetta, P, Mease, PJ, Merola, JF, Miner, J, Ritchlin, CT, Siaton, B, Smith, BJ, Voorhees, AS, Jonsson, AH, Shah, AA, Sullivan, N, Turgunbaev, M, Coates, LC, Gottlieb, A, Magrey, M, Nowell, WB, Orbai, AM, Reddy, SM, Scher, JU, Siegel, E, Siegel, M, Walsh, JA, Turner, AS, Reston, J